BNP Paribas Financial Markets Decreases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)

BNP Paribas Financial Markets trimmed its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 69.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 58,443 shares of the company’s stock after selling 132,711 shares during the quarter. BNP Paribas Financial Markets’ holdings in HUTCHMED were worth $1,141,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Rhumbline Advisers boosted its position in shares of HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after buying an additional 564 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of HUTCHMED by 9.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock valued at $226,000 after acquiring an additional 1,168 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of HUTCHMED by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after acquiring an additional 2,321 shares during the period. Blue Trust Inc. raised its holdings in shares of HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after purchasing an additional 3,057 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in HUTCHMED by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company’s stock valued at $1,060,000 after purchasing an additional 4,877 shares during the period. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Trading Up 2.8 %

Shares of NASDAQ:HCM opened at $17.54 on Tuesday. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The firm’s 50 day moving average price is $18.76 and its 200-day moving average price is $18.33. HUTCHMED has a twelve month low of $11.93 and a twelve month high of $21.92.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.